Fate Therapeutics Inc (FATE) stock
FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3021% below fair value
$1.05+0.03 (+2.94%)
Close on Nov 18, 2026Market cap $125.81MP/E –Yield –
Fate Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Fate Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$105.62M. For fiscal 2025 it was -$112.04M. The highest annual figure on record is -$12.15M in fiscal 2011.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$112.04M | – |
| FY2024 | Dec 31, 2024 | -$123.60M | – |
| FY2023 | Dec 31, 2023 | -$138.42M | – |
| FY2022 | Dec 31, 2022 | -$283.77M | – |
| FY2021 | Dec 31, 2021 | -$213.57M | – |
| FY2020 | Dec 31, 2020 | -$44.16M | – |
| FY2019 | Dec 31, 2019 | -$90.57M | – |
| FY2018 | Dec 31, 2018 | -$40.95M | – |
| FY2017 | Dec 31, 2017 | -$38.54M | – |
| FY2016 | Dec 31, 2016 | -$30.28M | – |
| FY2015 | Dec 31, 2015 | -$19.90M | – |
| FY2014 | Dec 31, 2014 | -$23.30M | – |
| FY2013 | Dec 31, 2013 | -$15.62M | – |
| FY2012 | Dec 31, 2012 | -$13.98M | – |
| FY2011 | Dec 31, 2011 | -$12.15M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$23.48M | – |
| Q1 FY2026 | Mar 31, 2026 | -$31.06M | – |
| Q4 FY2025 | Dec 31, 2025 | -$24.51M | – |
| Q3 FY2025 | Sep 30, 2025 | -$26.58M | – |
| Q2 FY2025 | Jun 30, 2025 | -$25.95M | – |
| Q1 FY2025 | Mar 31, 2025 | -$35.01M | – |
| Q4 FY2024 | Dec 31, 2024 | -$27.90M | – |
| Q3 FY2024 | Sep 30, 2024 | -$29.91M | – |
| Q2 FY2024 | Jun 30, 2024 | -$32.36M | – |
| Q1 FY2024 | Mar 31, 2024 | -$33.44M | – |
| Q4 FY2023 | Dec 31, 2023 | -$36.82M | – |
| Q3 FY2023 | Sep 30, 2023 | -$38.84M | – |
| Q2 FY2023 | Jun 30, 2023 | -$30.69M | – |
| Q1 FY2023 | Mar 31, 2023 | -$32.07M | – |
| Q4 FY2022 | Dec 31, 2022 | -$82.07M | – |
| Q3 FY2022 | Sep 30, 2022 | -$63.72M | – |
| Q2 FY2022 | Jun 30, 2022 | -$63.29M | – |
| Q1 FY2022 | Mar 31, 2022 | -$74.70M | – |
| Q4 FY2021 | Dec 31, 2021 | -$88.66M | – |
| Q3 FY2021 | Sep 30, 2021 | -$48.11M | – |
| Q2 FY2021 | Jun 30, 2021 | -$45.73M | -219.7% |
| Q1 FY2021 | Mar 31, 2021 | -$31.08M | – |
| Q4 FY2020 | Dec 31, 2020 | -$22.94M | – |
| Q3 FY2020 | Sep 30, 2020 | -$31.69M | – |
| Q2 FY2020 | Jun 30, 2020 | $38.21M | – |
| Q1 FY2020 | Mar 31, 2020 | -$27.74M | – |
| Q4 FY2019 | Dec 31, 2019 | -$28.13M | – |
| Q3 FY2019 | Sep 30, 2019 | -$21.10M | – |
| Q2 FY2019 | Jun 30, 2019 | -$22.10M | – |
| Q1 FY2019 | Mar 31, 2019 | -$19.24M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.14M | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.28M | – |
| Q2 FY2018 | Jun 30, 2018 | -$11.80M | – |
| Q1 FY2018 | Mar 31, 2018 | -$12.74M | – |
| Q4 FY2017 | Dec 31, 2017 | -$11.52M | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.13M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.28M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.61M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.59M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.55M | – |
See a number that looks wrong?